Vical Stock Price, News & Analysis (NASDAQ:VICL)

$1.82 -0.02 (-1.09 %)
(As of 01/19/2018 03:45 PM ET)
Previous Close$1.84
Today's Range$1.80 - $1.84
52-Week Range$1.66 - $3.70
Volume125,300 shs
Average Volume147,317 shs
Market Capitalization$22.88 million
P/E Ratio-1.70
Dividend YieldN/A
Beta1.84

About Vical (NASDAQ:VICL)

Vical logoVical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:VICL
CUSIP92560210
Phone+1-858-6461100

Debt

Debt-to-Equity RatioN/A
Current Ratio3.82%
Quick Ratio3.82%

Price-To-Earnings

Trailing P/E Ratio-1.70093457943925
Forward P/E Ratio-1.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.53 million
Price / Sales2.33
Cash FlowN/A
Price / CashN/A
Book Value$4.08 per share
Price / Book0.45

Profitability

Trailing EPS($1.07)
Net Income$-8,970,000.00
Net Margins-92.13%
Return on Equity-29.06%
Return on Assets-23.52%

Miscellaneous

Employees73
Outstanding Shares18,600,000

Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) posted its quarterly earnings data on Monday, October, 23rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The biotechnology company had revenue of $3.24 million for the quarter, compared to the consensus estimate of $3.60 million. Vical had a negative return on equity of 29.06% and a negative net margin of 92.13%. View Vical's Earnings History.

When will Vical make its next earnings announcement?

Vical is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Vical.

Where is Vical's stock going? Where will Vical's stock price be in 2018?

3 brokerages have issued 12 month target prices for Vical's stock. Their predictions range from $6.00 to $9.00. On average, they anticipate Vical's stock price to reach $7.50 in the next twelve months. View Analyst Ratings for Vical.

Who are some of Vical's key competitors?

Who are Vical's key executives?

Vical's management team includes the folowing people:

  • R. Gordon Douglas M.D., Independent Chairman of the Board (Age 80)
  • Vijay B. Samant, President, Chief Executive Officer, Director (Age 63)
  • Anthony Alan Ramos, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (Age 50)
  • Mammen P. Mammen Jr., Vice President - Clinical Vaccines (Age 51)
  • Lawrence Russell Smith, Vice President - Vaccine Research (Age 54)
  • Thomas E. Shenk Ph.D., Director
  • Richard M. Beleson, Independent Director (Age 61)
  • Gary A. Lyons, Independent Director (Age 66)
  • Robert C. Merton Ph.D., Independent Director (Age 70)
  • George J. Morrow, Independent Director (Age 64)

Who owns Vical stock?

Vical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.41%). Company insiders that own Vical stock include Anthony Alan Ramos, Gary A Lyons, Lawrence Russell Smith, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Institutional Ownership Trends for Vical.

Who bought Vical stock? Who is buying Vical stock?

Vical's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Company insiders that have bought Vical stock in the last two years include Gary A Lyons, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Insider Buying and Selling for Vical.

How do I buy Vical stock?

Shares of Vical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of Vical stock can currently be purchased for approximately $1.82.

How big of a company is Vical?

Vical has a market capitalization of $22.88 million and generates $14.53 million in revenue each year. The biotechnology company earns $-8,970,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Vical employs 73 workers across the globe.

How can I contact Vical?

Vical's mailing address is 10390 Pacific Center Ct, SAN DIEGO, CA 92121-4340, United States. The biotechnology company can be reached via phone at +1-858-6461100 or via email at [email protected].


MarketBeat Community Rating for Vical (VICL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vical (NASDAQ:VICL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$9.00$9.00
Price Target Upside: 278.79% upside278.79% upside271.90% upside273.44% upside

Vical (NASDAQ:VICL) Consensus Price Target History

Price Target History for Vical (NASDAQ:VICL)

Vical (NASDAQ:VICL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightReiterated RatingBuy$6.00N/AView Rating Details
8/8/2017Ifs SecuritiesReiterated RatingOutperformMediumView Rating Details
6/12/2017Rodman & RenshawReiterated RatingBuy -> Buy$9.00HighView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Vical (NASDAQ:VICL) Earnings History and Estimates Chart

Earnings by Quarter for Vical (NASDAQ:VICL)

Vical (NASDAQ VICL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
10/23/2017Q3 2017($0.25)($0.27)$3.60 million$3.24 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.30)$3.35 million$3.42 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.18)($0.25)$3.21 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.25)$2.92 million$3.16 millionViewListenView Earnings Details
11/3/2016Q3($0.25)($0.24)$4.60 million$2.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.28)($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.03)$6.88 million$4.60 millionViewN/AView Earnings Details
3/14/2016Q415($0.02)($0.03)$4.82 million$6.81 millionViewListenView Earnings Details
7/30/2015Q215($0.06)($0.03)$3.80 million$4.20 millionViewListenView Earnings Details
5/8/2015Q115($0.05)($0.04)$2.50 million$4.90 millionViewN/AView Earnings Details
2/26/2015Q414($0.05)($0.05)$3.58 million$4.82 millionViewN/AView Earnings Details
10/30/2014Q314($0.05)($0.05)$2.50 million$3.40 millionViewN/AView Earnings Details
7/31/2014Q214($0.05)($0.05)$1.90 million$4.50 millionViewN/AView Earnings Details
5/1/2014Q114($0.05)($0.04)$1.60 million$2.40 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)($0.03)$1.54 million$3.15 millionViewN/AView Earnings Details
10/31/2013Q313($0.10)($0.11)$1.82 million$1.50 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.11)($0.11)$1.70 million$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.11)($0.11)$2.02 million$1.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.10)($0.09)$1.64 million$2.32 millionViewN/AView Earnings Details
11/7/2012Q312($0.09)($0.09)$1.47 million$2.20 millionViewN/AView Earnings Details
8/1/2012($0.09)($0.09)ViewN/AView Earnings Details
5/2/2012Q1 2012($0.70)$0.03ViewN/AView Earnings Details
2/8/2012Q4 2011($1.20)($0.92)ViewN/AView Earnings Details
11/1/2011$0.11$0.22ViewN/AView Earnings Details
8/3/2011($0.12)($0.12)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.10)($1.21)ViewN/AView Earnings Details
2/10/2011Q4 2010($1.20)($0.94)ViewN/AView Earnings Details
11/9/2010Q3 2010($1.40)($1.19)ViewN/AView Earnings Details
8/3/2010Q2 2010($1.30)($1.50)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.30)($1.54)ViewN/AView Earnings Details
2/11/2010Q4 2009($1.30)($1.40)ViewN/AView Earnings Details
11/4/2009Q3 2009($1.30)($1.37)ViewN/AView Earnings Details
8/6/2009Q2 2009($1.50)($1.36)ViewN/AView Earnings Details
5/7/2009Q1 2009($1.80)($2.04)ViewN/AView Earnings Details
2/17/2009Q4 2008($2.20)($2.24)ViewN/AView Earnings Details
11/5/2008Q3 2008($2.20)($2.44)ViewN/AView Earnings Details
8/5/2008Q2 2008($2.40)($2.14)ViewN/AView Earnings Details
5/8/2008Q1 2008($2.30)($2.44)ViewN/AView Earnings Details
2/21/2008Q4 2007($2.00)($2.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vical (NASDAQ:VICL) Earnings Estimates

Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-0.62 EPS

Dividends

Dividend History for Vical (NASDAQ:VICL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Vical (NASDAQ VICL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.98%
Institutional Ownership Percentage: 15.40%
Insider Trades by Quarter for Vical (NASDAQ:VICL)
Institutional Ownership by Quarter for Vical (NASDAQ:VICL)

Vical (NASDAQ VICL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2017Robert C MertonDirectorBuy85,700$1.75$149,975.0095,451View SEC Filing  
3/27/2017Anthony Alan RamosVPSell4,250$2.17$9,222.50View SEC Filing  
1/11/2017Lawrence Russell SmithVPSell54$2.48$133.92View SEC Filing  
1/10/2017Vijay B. SamantCEOSell5,763$2.45$14,119.35View SEC Filing  
12/22/2016Robert C. MertonDirectorSell4,000$2.24$8,960.00View SEC Filing  
12/20/2016Robert C. MertonDirectorSell4,327$2.21$9,562.67View SEC Filing  
12/13/2016Vijay B. SamantCEOSell15,699$2.39$37,520.61View SEC Filing  
12/12/2016R Gordon DouglasDirectorSell10,078$2.39$24,086.42View SEC Filing  
10/11/2016Lawrence Russell SmithVPSell54$3.05$164.70View SEC Filing  
7/11/2016Lawrence Russell SmithVPSell54$4.46$240.84View SEC Filing  
6/14/2016Robert C MertonDirectorBuy9,000$4.34$39,060.0013,978View SEC Filing  
6/9/2016Vijay B SamantCEOBuy15,700$4.72$74,104.00112,632View SEC Filing  
6/6/2016R Gordon DouglasDirectorBuy10,078$4.41$44,443.9820,906View SEC Filing  
6/3/2016Gary A LyonsDirectorBuy7,078$4.39$31,072.4214,906View SEC Filing  
3/15/2016Lawrence Russell SmithVPSell8,750$0.41$3,587.50232,331View SEC Filing  
3/3/2016Vijay B SamantCEOSell37,500$0.36$13,500.00989,226View SEC Filing  
2/19/2016Anthony Alan RamosCAOSell7,500$0.33$2,475.00View SEC Filing  
1/25/2016Anthony Alan RamosCAOSell193$0.35$67.55146,735View SEC Filing  
1/12/2016Vijay B. SamantCEOSell59,737$0.35$20,907.951,006,826View SEC Filing  
1/11/2016Lawrence Russell SmithVPSell974$0.36$350.64241,081View SEC Filing  
1/11/2016Vijay B. SamantCEOSell48,535$0.35$16,987.251,006,826View SEC Filing  
1/7/2016Vijay B SamantCEOSell75,000$0.36$27,000.001,066,563View SEC Filing  
10/12/2015Lawrence Russell SmithVPSell974$0.43$418.82242,055View SEC Filing  
10/12/2015Vijay B SamantCEOSell4,738$0.41$1,942.581,141,563View SEC Filing  
7/13/2015Igor BilinskySVPSell1,258$0.70$880.60View SEC Filing  
7/13/2015Lawrence Russell SmithVPSell974$0.70$681.80View SEC Filing  
7/13/2015Vijay B SamantCEOSell4,737$0.70$3,315.90View SEC Filing  
4/13/2015Igor BilinskySVPSell1,257$0.93$1,169.01View SEC Filing  
4/13/2015Vijay B SamantCEOSell4,738$0.93$4,406.34View SEC Filing  
3/30/2015Vijay B SamantCEOSell55,000$0.91$50,050.00View SEC Filing  
1/13/2015Vijay B SamantCEOSell4,737$1.12$5,305.44View SEC Filing  
1/12/2015Igor BilinskySVPSell1,335$1.16$1,548.60View SEC Filing  
1/12/2015Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
10/13/2014Igor BilinskySVPSell1,335$1.08$1,441.80View SEC Filing  
10/13/2014Lawrence Russell SmithVPSell1,912$1.08$2,064.96View SEC Filing  
10/13/2014Vijay B SamantCEOSell4,738$1.13$5,353.94View SEC Filing  
8/26/2014Anthony Alan RamosCAOSell12,500$1.25$15,625.00View SEC Filing  
7/14/2014Vijay B SamantCEOSell4,737$1.17$5,542.29View SEC Filing  
7/11/2014Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
4/14/2014Vijay SamantCEOSell4,738$1.16$5,496.08945,988View SEC Filing  
4/11/2014Lawrence Russell SmithVPSell1,912$1.21$2,313.52193,213View SEC Filing  
1/10/2014Anthony Alan RamosCAOBuy70,000$1.42$99,400.00102,339View SEC Filing  
1/10/2014Igor BilinskyVPBuy90,000$1.42$127,800.00143,968View SEC Filing  
1/10/2014Vijay SamantCEOBuy330,000$1.42$468,600.00950,726View SEC Filing  
9/12/2013James R SingerMajor ShareholderSell200,000$1.29$258,000.00View SEC Filing  
9/11/2013James R SingerMajor ShareholderSell300,000$1.30$390,000.00View SEC Filing  
9/10/2013James R SingerMajor ShareholderSell200,000$1.23$246,000.00View SEC Filing  
9/9/2013James R SingerMajor ShareholderSell200,000$1.22$244,000.00View SEC Filing  
9/4/2013James Singermajor shareholderSell466,000$1.24$577,840.00View SEC Filing  
8/30/2013James Singermajor shareholderSell84,000$1.31$110,040.00View SEC Filing  
8/29/2013James Singermajor shareholderSell150,000$1.30$195,000.00View SEC Filing  
8/28/2013James Singermajor shareholderSell200,000$1.31$262,000.00View SEC Filing  
8/26/2013Anthony Alan RamosCAOBuy25,000$0.01$250.0040,665View SEC Filing  
5/23/2013Robert C MertonDirectorBuy5,953$0.01$59.53View SEC Filing  
1/11/2013Alain P Phd RollandVPBuy22,092$0.01$220.92View SEC Filing  
1/11/2013Jill Marie BroadfootCFOBuy27,060$0.01$270.60View SEC Filing  
1/11/2013Vijay B SamantCEOBuy84,600$0.01$846.00View SEC Filing  
10/15/2012George J MorrowDirectorBuy6,394$0.01$63.94View SEC Filing  
9/24/2012James R SingerMajor ShareholderBuy154,333$3.99$615,788.67View SEC Filing  
8/31/2012James R SingerMajor ShareholderBuy310,000$3.51$1,088,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vical (NASDAQ VICL) News Headlines

Source:
DateHeadline
Vical (VICL) Upgraded to "Hold" by Zacks Investment ResearchVical (VICL) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - December 26 at 10:38 AM
What You Must Know About Vical Incorporated’s (undefined:VICL) Financial HealthWhat You Must Know About Vical Incorporated’s (undefined:VICL) Financial Health
finance.yahoo.com - December 13 at 10:54 AM
Want To Invest In Vical Incorporated (VICL)? Here’s How It Performed LatelyWant To Invest In Vical Incorporated (VICL)? Here’s How It Performed Lately
finance.yahoo.com - December 5 at 12:16 PM
Vical (VICL) Lifted to Hold at Zacks Investment ResearchVical (VICL) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - December 2 at 7:42 AM
Are Options Traders Betting on a Big Move in Vical (VICL) Stock?Are Options Traders Betting on a Big Move in Vical (VICL) Stock?
finance.yahoo.com - November 24 at 6:29 PM
ETFs with exposure to Vical, Inc. : November 21, 2017ETFs with exposure to Vical, Inc. : November 21, 2017
finance.yahoo.com - November 22 at 4:35 PM
Vical Incorporated (VICL) Earns "Buy" Rating from HC WainwrightVical Incorporated (VICL) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - November 21 at 1:16 PM
Vical Incorporated (VICL) Director Acquires $149,975.00 in StockVical Incorporated (VICL) Director Acquires $149,975.00 in Stock
www.americanbankingnews.com - November 14 at 1:32 PM
Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common StockVical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock
finance.yahoo.com - November 9 at 9:29 AM
32 Stocks Moving In Wednesdays Pre-Market Session32 Stocks Moving In Wednesday's Pre-Market Session
feeds.benzinga.com - November 8 at 8:50 AM
ETFs with exposure to Vical, Inc. : November 6, 2017ETFs with exposure to Vical, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 1:00 PM
Reviewing Vical (VICL) & Its PeersReviewing Vical (VICL) & Its Peers
www.americanbankingnews.com - October 26 at 9:20 PM
ETFs with exposure to Vical, Inc. : October 26, 2017ETFs with exposure to Vical, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 11:58 AM
Vical Incorporated (VICL) Downgraded to "Sell" at Zacks Investment ResearchVical Incorporated (VICL) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 26 at 9:00 AM
Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017
finance.yahoo.com - October 25 at 4:00 PM
Vical Incorporateds (VICL) CEO Vijay Samant on Q3 2017 Results - Earnings Call TranscriptVical Incorporated's (VICL) CEO Vijay Samant on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 24 at 4:13 PM
Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B InfectionVical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection
finance.yahoo.com - October 24 at 11:59 AM
Edited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMT
finance.yahoo.com - October 24 at 11:59 AM
Vical teams up with AnGes to develop new HBV treatment; shares ahead 7% premarketVical teams up with AnGes to develop new HBV treatment; shares ahead 7% premarket
seekingalpha.com - October 24 at 8:26 AM
Vical Reports Third Quarter 2017 Financial and Operational ResultsVical Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - October 23 at 8:52 AM
Vical reports 3Q lossVical reports 3Q loss
finance.yahoo.com - October 23 at 8:52 AM
Vical Incorporated (VICL) Set to Announce Quarterly Earnings on MondayVical Incorporated (VICL) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 18 at 10:28 AM
Vical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial Results
feeds.benzinga.com - October 16 at 5:56 PM
Vical to Provide Company Update at BIO Investor Forum ConferenceVical to Provide Company Update at BIO Investor Forum Conference
finance.yahoo.com - October 14 at 9:11 AM
Vical (VICL) Reports Completion of the Phase 3 ASP0113 CMV Vaccine TrialVical (VICL) Reports Completion of the Phase 3 ASP0113 CMV Vaccine Trial
www.streetinsider.com - October 12 at 2:50 AM
Vical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarketVical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarket
seekingalpha.com - October 12 at 2:50 AM
ETFs with exposure to Vical, Inc. : October 11, 2017ETFs with exposure to Vical, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 4:47 PM
Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine TrialVical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
finance.yahoo.com - October 10 at 8:08 AM
Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy TrialVical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial
finance.yahoo.com - October 3 at 2:28 PM
Mid-stage study may suffice under LUI for Vicals antifungal VL-2397; shares ahead 37% after hoursMid-stage study may suffice under LUI for Vical's antifungal VL-2397; shares ahead 37% after hours
seekingalpha.com - October 2 at 5:42 PM
Vical to Present at IDWeek and the 8th Trends in Medical Mycology ConferencesVical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
globenewswire.com - September 28 at 9:23 AM
ETFs with exposure to Vical, Inc. : September 14, 2017ETFs with exposure to Vical, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 10:59 AM
Vical (VICL) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowVical (VICL) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 10:27 PM
Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 3:53 PM
Vical to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceVical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 7 at 10:47 AM
Vical Incorporated (NASDAQ:VICL) Stock Rating Reaffirmed by Ifs SecuritiesVical Incorporated (NASDAQ:VICL) Stock Rating Reaffirmed by Ifs Securities
www.americanbankingnews.com - August 11 at 4:00 PM
Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017
finance.yahoo.com - August 10 at 9:23 AM
Edited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMT
finance.yahoo.com - August 10 at 9:23 AM
Vical Incorporateds (VICL) CEO Vijay Samant on Q2 2017 Results - Earnings Call TranscriptVical Incorporated's (VICL) CEO Vijay Samant on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 8:55 AM
Vical Incorporated (VICL) Posts  Earnings Results, Misses Estimates By $0.02 EPSVical Incorporated (VICL) Posts Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 8 at 2:40 PM
Vical Reports Second Quarter 2017 Financial and Operational ResultsVical Reports Second Quarter 2017 Financial and Operational Results
finance.yahoo.com - August 8 at 8:04 AM
Vical reports 2Q lossVical reports 2Q loss
finance.yahoo.com - August 8 at 8:04 AM
Vical Incorporated (VICL) to Release Quarterly Earnings on TuesdayVical Incorporated (VICL) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 12:06 PM
Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 8:25 AM
ETFs with exposure to Vical, Inc. : June 30, 2017ETFs with exposure to Vical, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 8:46 AM
Vical to Present VL-2397 Data at the June ASM Microbe 2017 MeetingVical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
feeds.benzinga.com - May 23 at 7:09 AM
Vical misses by $0.07, misses on revenueVical misses by $0.07, misses on revenue
seekingalpha.com - May 15 at 6:43 AM
Vical revenues off 30% in Q1Vical revenues off 30% in Q1
seekingalpha.com - May 15 at 6:43 AM
Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
feeds.benzinga.com - May 8 at 7:07 AM
Vical (VICL) Finalizes Target Enrollment for Phase 2 Therapeutic HSV-2 Vaccine TrialVical (VICL) Finalizes Target Enrollment for Phase 2 Therapeutic HSV-2 Vaccine Trial
www.streetinsider.com - April 21 at 12:07 AM

SEC Filings

Vical (NASDAQ:VICL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vical (NASDAQ:VICL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vical (NASDAQ VICL) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.